Barclays raised its price target on Quidel Corp. (NASDAQ: QDEL) to $27.00 (from $26.00) while maintaining a Overweight rating. QDEL reported 1Q revenues of $73.7 million, beating estimates of $62.4 million by 18%. The beat was driven by a more aggressive-than-expected flu season.

Analyst Jack Meehan believes that the company's innovation in point-of-care testing fits well into broader trends related to healthcare consumerism.